Preventive experimental HIV vaccine trial

HVTN 092

Status: Study completed
Number of volunteers: 27
​​​​​​​Lenght of the study: 9 or 11
months

​​​​​​​A phase I clinical trial to evaluate safety and to compare the immunogenicity of 3 DNA vaccine prime schedules followed by a NYVAC vaccine boost in healthy, HIV-1 uninfected adult participants.

The aim of this phase I clinical trial is to evaluate a new HIV vaccines (DNA and NYVAC vaccines) injection schedule (accelerated schedule). The objective is to verify the safety of this accelerated schedule and to compare the immunogenicity induced with the one obtained with the historical schedule.

27 healthy volunteers, men and women, at low risk of HIV infection, aged 18-50 years old, will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, for 9 or 11 months, depending on the study group. A total of 9 or 11 visits are scheduled including a full medical check-up, 3 or 4 immunization visits and follow-up visits with blood samples.

For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163.

HVTN 096/EV04

Status: Study completed
Number of volunteers: 96
​​​​​​​Lenght of the study: 18
months

​​​​​​​A phase I double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus NYVAC + AIDSVAX® B/E, and DNA alone versus DNA + AIDSVAX® B/E when followed by NYVAC + AIDSVAX® B/E in healthy, HIV-1-uninfected adults participants.

The aim of this phase I clinical trial is, first, to evaluate the safety of different vaccine regimens using 3 vaccines against HIV (DNA, NYVAC and AIDSVAX® B/E) and secondly, to compare the immune response induced by these vaccine regimens in HIV-uninfected participants.

96 volunteers at low risk of HIV infection, aged 18-50 years old, men and women, will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, for 18 months. A total of 14 visits are scheduled including a full medical check-up, 4 immunization visits and 9 follow-up visits with blood samples.

For further information on this study, please contact us by phone +41 21 314 1160 / +41 21 314 1163.

Contact

Division of Immunology and Allergy
Monday to Friday: 8 am - 6 pm
Vaccine and Immunotherapy Center
1011 Lausanne, Suisse
Tél. +41 21 314 1160
Tél. +41 21 314 1163
Fax +41 21 314 1161
 Dernière mise à jour le 28/06/2019 à 08:09